Bradford School of Pharmacy, University of Bradford, Bradford, UK.
J Psychopharmacol. 2012 Sep;26(9):1265-70. doi: 10.1177/0269881111431747. Epub 2011 Dec 18.
The α7 nicotinic acetylcholine receptors (nAChRs) have been highlighted as a target for cognitive enhancement in schizophrenia. Adult female hooded Lister rats received sub-chronic phencyclidine (PCP) (2 mg/kg) or vehicle i.p. twice daily for 7 days, followed by 7 days' washout. PCP-treated rats then received PNU-120596 (10 mg/kg; s.c.) or saline and were tested in the attentional set-shifting task. Sub-chronic PCP produced a significant cognitive deficit in the extra-dimensional shift (EDS) phase of the task (p < 0.001, compared with vehicle). PNU-120596 significantly improved performance of PCP-treated rats in the EDS phase of the attentional set-shifting task (p < 0.001). In conclusion, these data demonstrate that PNU-120596 improves cognitive dysfunction in our animal model of cognitive dysfunction in schizophrenia, most likely via modulation of α7 nACh receptors.
α7 型烟碱型乙酰胆碱受体 (nAChRs) 已被确定为精神分裂症认知增强的靶点。成年雌性 hooded Lister 大鼠接受亚慢性苯环己哌啶 (PCP)(2 mg/kg)或载体腹腔内注射,每天两次,共 7 天,然后进行 7 天的清洗。PCP 处理的大鼠随后接受 PNU-120596(10 mg/kg;皮下注射)或生理盐水,并在注意力转换任务中进行测试。亚慢性 PCP 在任务的外维度转换 (EDS) 阶段产生了明显的认知缺陷(p < 0.001,与载体相比)。PNU-120596 显著改善了 PCP 处理大鼠在注意力转换任务的 EDS 阶段的表现(p < 0.001)。总之,这些数据表明 PNU-120596 改善了我们的精神分裂症认知功能障碍动物模型中的认知功能障碍,这很可能是通过调节 α7 nACh 受体实现的。